Last reviewed 2026-04-20 · How we verify

Cardura (DOXAZOSIN)

Cardura (Doxazosin) is a small molecule alpha-Adrenergic Blocker that targets the Alpha-1B adrenergic receptor. Originally developed by Pfizer and now owned by Viatris, it was FDA approved in 1990 for the treatment of Benign Prostatic Hyperplasia and Hypertensive disorder. As an off-patent medication, Cardura is available as a generic from multiple manufacturers. Key safety considerations include orthostatic hypotension and dizziness. Cardura's commercial status allows for generic competition, making it a widely available treatment option.

At a glance

Approved indications

• Benign prostatic hyperplasia
• Hypertensive disorder

Common side effects

• Dizziness
• Somnolence
• Hypotension
• Dyspnoea
• Dry Mouth
• Fatigue
• Oedema
• Dizziness
• Somnolence
• Rhinitis
• Polyuria
• Fatigue / Malaise

Drug interactions

• sildenafil
• tadalafil
• vardenafil

Key clinical trials

• Alpha-1 Blockade for Alcohol Use Disorder (AUD) (PHASE2)
• Doxazosin an a1 Antagonist for Alcohol Dependence (EARLY_PHASE1)
• Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism
• Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin (PHASE2)
• Doxazosin and Ramipril in Hypertension (PHASE4)
• Phenoxybenzamine Versus Doxazosin in PCC Patients (PHASE4)
• A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD (PHASE2)
• Genetics of Hypertension Associated Treatments (GenHAT)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.